HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

The ‘puzzle’ of noncompliance: Skipped radiation and lives lost

Joseph Ragaz, MD, FRCP

Enzalutamide extends PFS in castration-resistant prostate cancer

Cover Story

Experts: E-cigarette regulations necessary to balance potential benefits, unknown harms


Small molecules, ‘big data’ and the EMR

John Sweetenham, MD

FDA News

FDA strengthens warning, changes prescribing instructions for Feraheme

FDA grants orphan drug designation to IMO-8400 for DLBCL

FDA approves Jadenu for chronic iron overload

FDA grants fast track status to anticoagulant reversal agent PER977

FDA grants orphan drug designation to CUDC-907 for DLBCL

FDA grants orphan drug designation to CRS-207 for mesothelioma

In the Journals

Researchers identify age-associated risks for gastric, breast cancers with CDH1 mutations

Women with IBD may face higher cervical cancer risk

Nomograms predict risk for tumor progression, death in imatinib-treated patients with GIST

HSCT access limited by country, cost

Metronomic temozolomide extends PFS, OS in EGFR-amplified glioblastoma

One-third of patients do not receive recommended post-mastectomy radiation

Older patients with HNSCC face higher toxicity risk from chemotherapy, radiation

Benefits of tamoxifen for breast cancer prevention vary among at-risk women

Boosted PIs lower Kaposi sarcoma incidence

Advanced breast cancer more likely in women with diabetes

Advanced stage at diagnosis linked to worse lung adenocarcinoma OS

Antivirals improve CMV pneumonia outcomes after HCT

Changes in nevi were poor predictors of melanoma in children

Encouraging male HPV vaccination may extend protection against HPV infection

Combined-modality treatment effective for muscle-invasive bladder cancer

Adults with sickle cell disease display sleep disordered breathing

Data support predictive significance of superficial vein thrombosis

Meeting News Coverage

T-VEC extends OS in patients with unresected stage III/IV melanoma

Adjuvant ipilimumab prolongs RFS in stage III melanoma

HD IL-2 extends OS in malignant melanoma

Bevacizumab plus chemotherapy improves OS in recurrent ovarian cancer

Phase 3 trial to compare PV-10 with chemotherapy in stage III melanoma